BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

Active, not recruitingOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 1, 2024

Study Completion Date

June 30, 2025

Conditions
Non Hodgkin LymphomaFollicular LymphomaMarginal Zone LymphomaDiffuse Large B Cell Lymphoma
Interventions
OTHER

Histopathological analysis

"Morphological analysis will include the description of architectural patterns and cytological features on formalin-fixed and paraffin-embedded (FFPE) tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud.~A panel of immunohistochemical staining will be analyzed including CD20, CD3, CD10, Bcl-6, Bcl-2, CD5, CD23, CD38, MUM1, Ig kappa, Ig lambda, MEF2B, LMO2, MNDA, IRTA1, P53, CMYC and Ki67 . /MIB1. Diffuse large B-cells lymphomas will be classified into two distinct subgroups: centro-germinative (GC) and non-centro-germinative (nGC), using the Hans algorithm."

GENETIC

Molecular analysis

"Next-generation sequencing (NGS) analysis will be performed on FFPE tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud. A panel of 73 genes dedicated to lymphoma diagnosis determined by a consensus of French Lysa experts will be used. The identification of genetic variants will be followed by the attribution of pathogenicity class in accordance with the guidelines for validation of NGS-based oncology panels.~RNA extraction will classify DLBCLs into two distinct subgroups: germinal-centre B-cell-like (GCB-DLBCL) and activated B-cell-like (ABC-DLBCL)."

Trial Locations (1)

69495

Hopital Lyon Sud - HCL, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT06424379 - BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. | Biotech Hunter | Biotech Hunter